Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Genmab A/S (GMXAY)

Genmab A/S (GMXAY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K N/A
  • Shares Outstanding, K N/A
  • Annual Sales, $ 0 K
  • Annual Income, $ 0 K
  • 60-Month Beta N/A
  • Price/Sales N/A
  • Price/Cash Flow 207.45
  • Price/Book 12.90
Trade GMXAY with:
  • Price/Earnings ttm N/A
  • Earnings Per Share ttm N/A
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date N/A
  • Annual Dividend & Yield N/A (N/A)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Price Performance

See More
Period Period Low Period High Performance
1-Month
17.4650 +5.07%
on 06/27/19
19.0000 -3.42%
on 07/08/19
+0.4300 (+2.40%)
since 06/17/19
3-Month
16.3300 +12.37%
on 05/13/19
19.0000 -3.42%
on 07/08/19
+1.4100 (+8.32%)
since 04/17/19
52-Week
12.1000 +51.65%
on 10/25/18
19.0000 -3.42%
on 07/08/19
+0.8500 (+4.86%)
since 07/17/18

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Genmab A/S, incorporated on June 11, 1998, is a biotechnology company that utilizes antibody products. The Company's first marketed antibody, ofatumumab (Arzerra), was approved to treat chronic lymphocytic leukemia in patients who are refractory to fludarabine and alemtuzumab. Ofatumumab is marketed...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 18.4300
1st Resistance Point 18.3900
Last Price 18.3500
1st Support Level 18.2700
2nd Support Level 18.1900
3rd Support Level N/A

See More

52-Week High 19.0000
Last Price 18.3500
Fibonacci 61.8% 16.3642
Fibonacci 50% 15.5500
Fibonacci 38.2% 14.7358
52-Week Low 12.1000

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar